



D1

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification<sup>6</sup> :

B01D 15/08, G01N 30/60

A1

(11) International Publication Number:

WO 99/00168

(43) International Publication Date:

7 January 1999 (07.01.99)

(21) International Application Number: PCT/US98/13163

(22) International Filing Date: 24 June 1998 (24.06.98)

(30) Priority Data:

60/051,756

27 June 1997 (27.06.97)

US

(71) Applicant: BIOSEPPRA, INC. [US/US]; 111 Locke Drive,  
Marlborough, MA 01752 (US).(72) Inventor: COFFMAN, Jonathan, L.; 253 Brookstation Road,  
Princeton, MA 01541 (US).(74) Agents: CLEMENT, Candice, J. et al.; Heslin & Rothenberg,  
P.C., 5 Columbia Circle, Albany, NY 12203 (US).(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR,  
BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE,  
GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ,  
LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW,  
MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,  
TM, TR, TT, UA, UG, UZ, VN, YU, ZW, ARIPO patent  
(GH, GM, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent  
(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent  
(AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT,  
LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI,  
CM, GA, GN, ML, MR, NE, SN, TD, TG).


Published

With international search report.

(54) Title: ONE STEP DEVICE AND PROCESS FOR CONCENTRATION AND PURIFICATION OF BIOLOGICAL MOLECULES

## (57) Abstract

A device for one step purification of a desired biological molecule from a sample, wherein the device comprises a housing loaded with an adsorptive media of a known volume on top of a size exclusion media of a known volume, and a method of purifying biological molecules using the same.



**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Larvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand		
CM	Cameroon		Republic of Korea	PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

## ONE STEP DEVICE AND PROCESS FOR CONCENTRATION AND PURIFICATION OF BIOLOGICAL MOLECULES

### Field of Invention

5           The present invention relates to devices and methods for concentrating and purifying biological molecules.

### Background of Invention

10           There are many devices used in purification of molecules where an adsorptive media is packed into the bottom of a syringe-like object, or in the wells of a multiwell plate. Typically, the target solute is eluted in a buffer that is unfavorable to further analysis, and the solute must be further processed to remove or exchange the eluting buffer with another buffer favorable for further analysis or other use.

15           An example of such is an elution from an ion exchange column, wherein the solute of interest is eluted from the column in a high salt buffer. However, many subsequent analyses of the solute of interest, including, *e.g.*, electrophoresis or enzymatic digests of plasmid DNA, cannot be performed satisfactorily in this high salt environment. Thus, at present, such a sample is often desalted with dialysis or with a separate gel permeation or size exclusion chromatography ("SEC") device, or for plasmid purification, the DNA is precipitated from the salt solution with a variety of precipitants, including  
20           ethanol, isopropanol, PEG4000, and the like. (*See, e.g.*, U.S. Patent No. 5,057,426 to Henco *et al.*)

25           In addition, prior to the present invention, adsorptive chromatography devices which used multiwell plates required a two step/two plate method in order to achieve purification, by *e.g.*, ion exchange, and subsequent separation of the desired product from the high salt content of the elution buffer. This required using two separate chromatography steps and two multiwell plates, thereby undesirably increasing both the time and cost of such purification methods.

### Summary of Invention

30           The device and methods of the present invention overcome the disadvantages of previous means of purifying biological molecules by combining the adsorptive chromatography step with the SEC step (*e.g.*, desalting), thereby allowing the desired product or biological molecules of interest to be eluted in a buffer that facilitates further

processing, such as gene transfection or analysis by electrophoresis, using a single chromatography process and a single plate.

In one aspect the present invention relates to a device for purifying or separating a desired product or biological molecule of interest which comprises a housing having an outlet disposed at a bottom end, wherein a porous material is disposed over the outlet, a size exclusion media portion comprising a volume of a size exclusion media packed in the housing on top of said porous material, and an adsorptive media portion comprising a volume of adsorptive media packed in the housing on top of said size exclusion media portion. In a preferred embodiment, the housing is a well of a multiwell plate.

In another embodiment, the device further comprises a removable porous material, such as a porous frit or membrane, disposed on top of the adsorptive media portion of the device.

Another aspect of the present invention relates to methods for separating or purifying a desired product or biological molecules of interest from a sample or mixture which comprises preequilibrating a device of the present invention with a buffer solution, loading the resulting preequilibrated device with a sample or mixture which comprises the desired product or biological molecules of interest and undesired impurities, then washing the loaded device with a buffer (1), and thereafter charging the device with a preferred buffer (2) which saturates the size exclusion media in the device of the present invention, eluting the biological molecules of interest by loading the device with a volume an elution buffer (3) and collecting the biological molecules of interest in the preferred buffer (2).

In a preferred embodiment, the volume of elution buffer (3) present is about 5 % to about 50% of the volume of size exclusion media packed into the device of the present invention.

In another embodiment, preferred buffer (2) is present in a volume which comprises the total volume of adsorptive media and size exclusion media packed in the device of the present invention, and optionally, an additional volume which is in the range of about 1 % to about 600 % of the total volume of adsorptive media and size exclusion media packed into the device. In a preferred embodiment, the additional volume of preferred buffer (2) is about 5 % to about 400 %, and more preferably, about 10 % to about 60 % of the total volume of adsorptive media and size exclusion media packed into the device of the present invention.

A further aspect the present invention relates to a device for purifying a desired product or biological molecules of interest which comprises a housing having an outlet disposed at a bottom end, wherein a porous material is disposed over the outlet, a size exclusion media portion comprising a volume of a size exclusion media packed in the housing on top of said porous material, and a surfactant portion comprising a surfactant layer disposed on top of said size exclusion media portion.

#### **Brief Description of the Drawings**

Figure 1 depicts a side view of a device according to the present invention wherein a housing (11) having an opening (16) in the bottom of the housing and a porous material (12) disposed over the opening, is loaded with adsorptive media (13), which is loaded on top of an SEC media (14), leaving a reservoir (15) above the adsorptive media (13).

Figure 2 depicts a side view of another device according to the present invention wherein a housing (11) having an opening (16) in the bottom of the housing and a porous material (12) disposed over the opening, is loaded with a thin layer of a surfactant (17) which is loaded on top of an SEC media (14), leaving a reservoir (15) above the surfactant (17).

#### **Detailed Description of the Invention**

The present invention relates to a device for separation or purification of a solute of interest using a device wherein a volume of adsorptive media is loaded on top of a volume of SEC media. The solute of interest is adsorbed onto the adsorptive media, but is excluded from the SEC media upon elution.

In the present specification, the terms "size exclusion chromatography media", "SEC media", and "size exclusion media" will be used interchangeably to refer to the size exclusion chromatography media used in the present invention.

According to the present invention, in order to purify or separate biological molecules, the SEC step is combined with the adsorptive step in a single device, as shown in Figure 1. The device of the present invention is particularly useful for purifying or separating products that are much larger than the undesired molecules contained in the elution buffer, such that, on a relative basis, the desired product is excluded from the SEC media, while the undesired molecules in the buffer enter the SEC media.

The present invention allows the desired product to be eluted in any buffer of

choice in a single or "one step" process in a small laboratory device or high speed device. The buffer of choice can be any relatively small molecular weight compound compared with the molecular weight of the desired product. Examples of such buffers include low molecular weight TRANSFECTAM™, low molecular weight polyethyleneimine ("PEI"), and Tris HCl of any salt concentration or desired pH.

Using the device of the present invention, the desired product or solute of interest is adsorbed onto the adsorptive media. It is then washed with a buffer (1) in order to remove loosely bound solutes. Then, the device is loaded with a preferred buffer (2) to charge the SEC media portion of the device with the preferred buffer (2).

An elution buffer (3) is then passed through the device or column, which causes the desired product to desorb from the adsorptive media. The solute then passes into the SEC media section of the device, and a typical size exclusion (*e.g.*, desalting) operation occurs. The desired product or solute of interest is excluded from the interior part of the SEC media. Thus, the desired product or solute of interest travels faster in the SEC media portion of the device than does the elution buffer (3). The desired product or solute of interest therefore overtakes the preferred buffer (2) and exits the device in this preferred buffer (2). The volume of the elution buffer (3) is carefully controlled so that it remains in the device, and does not exit with the desired product and the preferred buffer (2).

The geometry of the device of the present invention, and the reservoir for the buffers can be varied for convenience.

Adsorptive chromatography media for use in the device of the present invention include, but are not limited to, media such as reversed phase media, ion exchange media, normal phase media, hydroxyapatite media, metal chelating media, affinity media, and any other media which binds molecules in one buffer, and releases molecules in a different buffer. For example, adsorptive chromatography media may be selected from the group consisting of PLASMIDEX™ 20μ (commercially available from BioSeptra, Inc., Marlborough, MA USA), Q FAST FLOW (commercially available from Pharmacia Biotech, Uppsala Sweden), QIAGEN PLASMID MEDIA (commercially available from Qiagen Inc., Chatsworth, CA USA).

The amount of adsorptive media present in the device of the present invention can vary depending on the adsorptive media used and the size of the device housing. In general, the packed volume of media used as the adsorptive media portion of the device

of the present invention is about 10  $\mu$ l to about 2000  $\mu$ l. Preferably, the packed volume of the adsorptive media portion is about 10  $\mu$ l to about 50  $\mu$ l, and more preferably about 15  $\mu$ l to about 25  $\mu$ l.

Media useful as size exclusion or SEC media in the device of the present invention should allow the impurities in a sample to penetrate the SEC media to a greater extent than the desired product or solute of interest in the sample. In addition, the SEC media should be rigid enough to allow a useful pressure drop in order to force flow through the media. For example, SEC media for use in the present invention include, but are not limited to, ACA media, such as ACA 34, ACA 44, ACA 54, and ACA 200 (commercially available from BioSeptra, Inc., Marlborough, MA USA), GF05 and GF2000 (commercially available from BioSeptra, Inc., Marlborough, MA USA), Sephacryl media, such as S400, S500, and S-1000 (commercially available from Pharmacia Biotech, Uppsala, Sweden), Superdex media, such as Superdex 75 and Superdex 200 (commercially available from Pharmacia Biotech, Uppsala, Sweden), and the like. In one embodiment, the size exclusion media is a SEC desalting media.

The present invention can further be used to remove any lower molecular weight compounds, including but not limited to, proteins, enzymes, endotoxins, and RNA, from a sample, such as a plasmid-containing sample, by selection of an appropriate SEC media. The characteristics of various SEC media which may be used in the present invention are known in the art, and thus selection of an appropriate SEC media for purification of a particular sample will be readily apparent to the skilled artisan.

The amount of SEC media present in the device of the present invention can vary depending on the SEC media used and the size of the device housing. In general, the packed volume of media used in the size exclusion media portion of the device of the present invention is about 30  $\mu$ l to about 6000  $\mu$ l. Preferably, the packed volume of size exclusion media is about 40  $\mu$ l to about 300  $\mu$ l, and more preferably about 45  $\mu$ l to about 100  $\mu$ l.

In general, when used in the methods for separating or purifying a desired product or solute of interest according to the present invention, the packed volume of the SEC media should be between about 2 times to about 10 times the volume of the elution buffer (3).

In other embodiments, the SEC media portion of the device of the present

invention can be changed to various other media having different adsorptive characteristics from the main adsorptive media, including but not limited to, hydrophobic interaction media which may selectively retain (or repel) the desired product, but repel (or retain) the buffer. An example of hydrophobic interaction media is media which will  
5 bind proteins at high salt concentrations, but elute proteins at low salt concentrations, thus effecting a one step separation of the desired product from other solutes in the first adsorptive media portion of the device, and then the desired product from the undesired elution buffer (salt) in the hydrophobic interaction media portion of the device.

Housings for use in the present invention can be readily determined by the skilled  
10 artisan. Such housings may include, but are not limited to, syringe-like devices, tubes, and wells of a multiwell plate, including, but not limited to 4-well, 16-well, 96-well, and 364-well multiwell plates. A porous material, such as a porous frit or membrane, is placed in the bottom of the housing prior to loading the various media in order to prevent the media from seeping out of the bottom hole of the housing during loading. Porous  
15 materials, including but not limited to porous frits or membranes, which may be used in the device of the present invention are well known in the art. Examples of porous frits include, but are not limited to, polypropylene frits having pore sizes ranging from about 0.45  $\mu\text{m}$  to about 50  $\mu\text{m}$ , and preferably from about 1  $\mu\text{m}$  to about 20  $\mu\text{m}$  (such frits are commercially available from Porex Technologies, Fairburn, GA USA).

20 In one embodiment of the device of the present invention, the device may further include a removable porous material, such as a porous frit or membrane, disposed on top of the adsorptive media portion of the device. This removable porous material may be left in place or removed when using the device to perform purification or separation operations, and preferably, the removable porous material is removed prior to use.

25 The present invention also relates to a method for purifying a desired product or biological molecule of interest using the device of the present invention. Essentially, the device of the present invention is preequilibrated with a buffer solution, then the resulting preequilibrated device is loaded with a sample or mixture comprising the desired product and undesired impurities. Thereafter, the loaded device is washed with a buffer (1),  
30 wherein said buffer (1) removes loosely bound impurities from the device while leaving the desired product in the device. The device is then washed with a preferred buffer (2), wherein preferred buffer (2) flows through an adsorptive media portion of the device into



a size exclusion media portion of the device, and the volume of preferred buffer (2) is sufficient to saturate the size exclusion media with the preferred buffer (2). The desired product is then eluted using a predetermined volume of an elution buffer (3), wherein the volume of elution buffer (3) is controlled to avoid elution with the desired product and preferred buffer (2).

The present invention provides the advantage of a combined or "one step" adsorptive and size exclusion (*e.g.*, desalting) process, for delivering a desired solute of a relatively high molecular weight in a buffer of relatively low molecular weight which does not interfere with subsequent use of the desired solute, while removing the desired solute from the elution buffer. Thus, the device and methods of the present invention minimize the number of steps and amount of equipment required, and saves the user time and money.

Preequilibration buffers for use in the present invention may include, but are not limited to, 50 mM Tris pH 8, 0 to 2M NaCl or 50 mM MOPS 0-2 M NaCl, or other buffer/salt combinations. In general, the pH of the preequilibration buffer will be in the range of about pH 1 to about pH 12. A preferred preequilibration buffer is 500 mM NaCl, 50 mM Tris pH 8.

Buffers for use as buffer (1), or the wash buffer according to method of the present invention generally are selected from salt buffers, wherein the choice of salt is dictated by what salt could elute the impurities but not the desired product, *e.g.*, plasmids, in a particular sample. Examples of buffers suitable for use as buffer (1) include, but are not limited to, 500 mM to 2 M NaCl in a buffer such as Tris pH 8, Tris pH 7, MOPS, or other suitable buffers.

Buffers for use as the preferred buffer (2) according to the methods of the present invention are selected from buffers or buffer combinations which are compatible with further processing of the desired product, such as a plasmid. Examples of buffers suitable for use as preferred buffer (2) include, but are not limited to, water, 50 mM Tris, 50 mM Tris and 5 mM EDTA, TRANSFECTUM™, SUPERFECTUM™, LIPOFECTUM™, enzymatic digest solutions containing enzymes or endonucleases, such as Hind III, EcoRI or other enzymes useful for sequencing of DNA, and the like, and combinations thereof.

The volume of preferred buffer (2) used in the methods of the present invention should be sufficient to saturate the SEC media portion of the device. In general, the

volume of preferred buffer (2) used will be roughly equal to the packed volume of the adsorptive media in the device plus the packed volume of the SEC media in the device, and may optionally include an additional volume for robustness, which additional volume is in the range of about 1 % to about 600 % of the total packed volume of the media loaded into the device, and preferably about 5 % to about 400 %, and more preferably, about 10 % to about 60 % of the total packed volume of media loaded into the device

Buffers for use as elution buffer (3), or the elution buffer, according to methods of the present invention include high salt buffers, such as NaCl, KCl, MgCl<sub>2</sub>, or CaCl<sub>2</sub> buffered with buffers known to those skilled in the art, such as Tris buffer, MOPS buffer, Acetate buffer, phosphate buffer, and the like.

The volume of the elution buffer (3) should be carefully controlled such that the elution buffer does not leave the device, or that the elution buffer leaves the device at a specific and predictable volume, so that the elution buffer does not mix with the desired product which is in preferred buffer (2). In general, the volume of elution buffer (3) used in the method of the present invention will be in the range of about 5 % to about 50 % of the packed volume of the SEC media.

When using the methods of the present invention to purify a desired product or solute of interest, it is preferable that the buffers used for both preferred buffer (2) and elution buffer (3) do not have a molecular weight on the same order as the molecular weight of the desired product or solute of interest.

Various types of samples may be purified using the present invention, including, but not limited to, a crude plasmid solution, such as that obtained from potassium acetate precipitation according to known methods (*see, e.g., Molecular Cloning*, Sambrook, Fritsch, Maniatis, Cold Spring Harbor, Plainview, NY (1989)), and plasmid or genomic DNA prepared using a variety of other methods well known in the art. In one embodiment, the sample containing the desired product is a clear *E. coli* cell lysate which is precipitated with potassium acetate, such as 1.32 M potassium acetate at pH 4.8.

In general, the desired product or solute of interest to be purified from a sample according to the present invention should be sufficiently larger than the undesirable molecules and impurities contained in the sample, such that on a relative basis, during the elution step of the present invention, the desired product or solute of interest would be excluded from the SEC media while the undesirable molecules and impurities would

enter the SEC media. In this manner, any smaller molecular weight molecules, such as RNA, endotoxins, proteins, *etc.*, can be separated from larger molecular weight molecules, such as plasmid DNA and genomic DNA, by using an appropriately sized SEC media, wherein said SEC media is sized with respect to the exclusion limit of the SEC media.

Note that while endotoxins are smaller molecular weight molecules than plasmids and other large nucleic acids, it is known that endotoxins can typically be found in micelles, which have a very large effective size, and do not enter the pores of most SEC media. Also, endotoxin micelles often coelute from ion exchangers with plasmids and other large nucleic acids. These endotoxins are not, however, desirable in plasmid preparations. Thus, it is desirable to separate endotoxins from the desired plasmid or other larger molecular weight products.

Accordingly, surfactants may be used to break up endotoxin micelles, thereby making the endotoxins small enough to enter the pores of a SEC media and be retained by the media relative to the desired product, such as plasmids or larger molecular weight molecules. Thus, the elution buffer (3) for removing the desired product from, for instance, the adsorptive media may comprise a high salt buffer in order to elute the desired product and an amount of a surfactant such that endotoxin micelles are broken up. The elution buffer (3) then pushes both the desired product and endotoxins into the SEC media portion of the device, where the endotoxins are retained by the SEC media, and the desired product goes through the interstices of the SEC media and elutes in preferred buffer (2). Surfactants, *e.g.*, such as 1% to 10% Triton X100 or X114, or sodium dodecyl sulfate ("SDS"), are small molecular weight solutes, and are retained by the SEC media. Hence, the SEC media retains the salt, surfactant, endotoxins, and other small molecule impurities, including RNA and proteins, while the desired product is eluted in preferred buffer (2).

Accordingly, in another embodiment of the present invention, elution buffer (3) comprises a salt buffer to desorb the desired product, such as plasmids or other large molecular weight molecules, from the adsorptive media portion of the device of the present invention and a surfactant to break up endotoxin micelles. Surfactants for use in elution buffer (3) include, but are not limited to, Triton X100, Triton X114, SDS, Brij, and other similar surfactants.

In another embodiment, the present invention relates to a device for purifying a desired product or solute of interest, such as plasmid DNA or genomic DNA, which comprises a housing having a porous material, such as a porous frit or membrane, on the bottom thereof, loaded with a thin layer of surfactant which is loaded on top of a SEC media, as shown in Figure 2. This device may be used to separate a desired product, such as a plasmid or other large molecular weight molecule, by precharging the SEC media with preferred buffer (2), loading the device with a sample or mixture containing the desired product and undesired impurities, and eluting the desired product using any appropriate buffer. According to this method, the surfactant layer of the device contacts the sample comprising the desired product and impurities, such as endotoxins, upon their delivery to the device, and any endotoxin micelles present in the sample disintegrate. Subsequently, the disintegrated endotoxin micelles enter the pores of the SEC media, while the desired product passes through the surfactant and elutes through void volume of the SEC media in preferred buffer (2) which is precharged in the SEC media.

The invention is further defined by reference to the following examples that describe in detail preparation of a one step device for purifying a desired product or biological molecule of interest, and methods of using the same according to the present invention. It will be apparent to those skilled in the art that many modifications, both to materials and methods, may be practiced without departing from the purpose and scope of this invention. The following examples are illustrative only and should in no way limit the scope of the present invention.

### EXAMPLE 1

Clear lysate samples were prepared in the following manner for use the examples herein. *E. coli* DH5 $\alpha$  containing the plasmid pSV-  $\beta$ GAL was inoculated into each of several flasks containing 120 ml of LB/Amp  $\beta$ -galactose media, and grown overnight at 37 °C. The cultures were then harvested by centrifuging in a Beckman G6 centrifuge for 15 minutes at about 3000 rpm.

The resulting pellets were then each resuspended in 5 ml of resuspension media (Promega, Madison, WI USA), and RNAase (Qiagen Inc., Chatsworth, CA USA) was added to a concentration of 100  $\mu$ g/ml. 5 ml of lysis buffer (Promega, Madison, WI USA) was then added, the samples were inverted, and allowed to sit for 5 minutes at room temperature.

Thereafter, 5 ml of neutralization buffer (Promega, Madison, WI USA) was added to each sample, the samples mixed and inverted, and spun in a Sorval, SS 34 rotor for 30minutes at about 12,000 rpm.

The resulting supernatants were then collected in 3 ml aliquots, and frozen for later use.

Prior to using the lysate samples in the subsequent examples. the frozen lysate samples were thawed, and precleared by spinning for about 8 minutes at 4°C, and then the cleared lysates were transferred to new tubes.

### EXAMPLE 2

In 3 mm diameter tubes having frits fitted into the bottom, the following media were loaded:

**Table 1**

	<b>Desalting Media</b>	<b>Adsorption Media</b>
Tube 1	150 $\mu$ l of 50 % ACA 44 slurry	50 $\mu$ l of 40% PLASMIDEX™ 20 $\mu$ slurry
Tube 2	---	50 $\mu$ l of 40% PLASMIDEX™ 20 $\mu$ slurry
Tube 3	---	37.5 $\mu$ l of 40% PLASMIDEX™ 20 $\mu$ slurry
Tube 4	---	37.5 $\mu$ l of 40% PLASMIDEX™ 20 $\mu$ slurry

Tube 1 was first packed with 150  $\mu$ l of a 50% ACA 44 slurry (commercially available from BioSeptra, Inc., Marlborough, MA USA), and vacuumed from the bottom

of the tube to remove excess fluid from the top of the bed. Tube 1 was then packed with 50  $\mu$ l of a 40 % PLASMIDEX™ 20 $\mu$  slurry (a 20  $\mu$ m quaternary amine anion exchange media commercially available from BioSeptra, Inc., Marlborough, MA USA), and vacuumed again from the bottom to remove excess interstitial fluid. Similarly, Tube 2 was packed with 50  $\mu$ l of 40% PLASMIDEX™ 20 $\mu$  slurry, and Tubes 3 and 4 were each packed with 37.5  $\mu$ l of 40% PLASMIDEX™ 20 $\mu$  slurry.

Each of Tubes 1 through 4 were then preequilibrated with 400  $\mu$ l of 0.5 M NaCl, 50 mM Tris pH 7.0.

600  $\mu$ l of a sample from Example 1, which comprise a clear lysate from a culture of *E. coli* DH5 $\alpha$  containing pSV-  $\beta$ GAL (the desired plasmid product) and undesirable contaminants, was then added to each of Tubes 1, 2, 3 and 4. The flow through from each tube was collected, and designated as samples 1f, 2f, 3f, and 4f, respectively.

Each tube was then washed with 400  $\mu$ l of 0.5 M NaCl, 50 mM Tris pH 7.0. The wash from Tubes 1, 2, 3, and 4 were collected and labeled as samples 1w, 2w, 3w, and 4w, respectively. In addition, Tube 1 was loaded with 400  $\mu$ l of distilled water (as preferred buffer (2)).

Each tube was then eluted twice with 25  $\mu$ l of the following elution buffers:

Tubes 1 and 2	2 M NaCl, 50 mM Tris pH 8.5;
Tube 3	2 M CaCl <sub>2</sub> , 50 mM Tris pH 8.5; and
Tube 4	2 M NaCl, 50 mM Tris pH 8.5.

Flow through was collected after each elution step, and the samples for Tubes 1, 2, 3, and 4 from the first elution step were designated 1e<sub>1</sub>, 2e<sub>1</sub>, 3e<sub>1</sub>, and 4e<sub>1</sub>, respectively, and the samples from the second elution step were designated 1e<sub>2</sub>, 2e<sub>2</sub>, 3e<sub>2</sub>, and 4e<sub>2</sub>, respectively.

Except for elution samples 1e<sub>1</sub> and 1e<sub>2</sub> collected from Tube 1, in order to aid in precipitation, to each of the elution samples the following were added: 12.5  $\mu$ l of 2M NaCl, 165  $\mu$ l of TE Buffer, and 140  $\mu$ l isopropanol. 420  $\mu$ l of isopropanol were added to each of the flow through samples 1f, 2f, 3f, and 4f, and 280  $\mu$ l of isopropanol were added to each of the wash samples 1w, 2w, 3w, and 4w. These samples were then vortexed and allowed to sit on ice for 60 minutes.

The samples were then centrifuged in a Beckman G6 centrifuge for 20 minutes, and the supernatant decanted. Each tube was then washed with 500  $\mu$ l of 70% ethanol at - 20°C, centrifuged for 6 minutes, and the supernatant decanted. The tubes were then

allowed to air dry for 30 minutes, and were resuspended in 30  $\mu$ l of TE Buffer.

5  $\mu$ l of each sample, including samples 1e<sub>1</sub> and 2e<sub>2</sub>, were then loaded onto a 1 % agarose gel run at 100 V for 60 minutes. More specifically, lanes 1 through 4 were loaded with 5  $\mu$ l of samples 1f, 1w, 1e<sub>1</sub>, and 1e<sub>2</sub>, respectively; lanes 5 through 8 were loaded with 5  $\mu$ l of samples 2f, 2w, 2e<sub>1</sub>, and 2e<sub>2</sub>, respectively; lanes 9 through 12 were loaded with 5  $\mu$ l of samples 3f, 3w, 3e<sub>1</sub>, and 3e<sub>2</sub>, respectively; and lanes 13 through 16 were loaded with 5  $\mu$ l of samples 4f, 4w, 4e<sub>1</sub>, and 4e<sub>2</sub>, respectively.

In addition, a 1/50 dilution of each elution sample and a 1/25 dilution of each flow through and wash sample were placed in quartz cuvettes, and the optical density ("OD") of each sample was measured using a UV spectrometer at 260 nm and 280 nm. The results from the UV spectroscopy are set forth in Table 2.

**Table 2**

Sample	Sample Volume	260 nm	280 nm	ratio 260:280	mg/ml	Yield (g)
1f	30 $\mu$ l	0.006	0.005	1.2	0.008	0.2 $\mu$ g
1w	30 $\mu$ l	0.005	0.004	1.2	0.006	0.2 $\mu$ g
1e <sub>1</sub>	25 $\mu$ l	0.402	0.202	1.99	1.005	25.1 $\mu$ g
1e <sub>2</sub>	25 $\mu$ l	0.085	0.044	1.93	0.213	5.3 $\mu$ g
2f	30 $\mu$ l	0.006	0.004	1.2	0.008	0.2 $\mu$ g
2w	30 $\mu$ l	0.004	0.003	1.3	0.005	0.2 $\mu$ g
2e <sub>1</sub>	30 $\mu$ l	0.411	0.216	1.9	1.028	30.9 $\mu$ g
2e <sub>2</sub>	30 $\mu$ l	0.014	0.008	1.75	0.035	1.1 $\mu$ g
3f	30 $\mu$ l	0.010	0.006	1.67	0.013	0.4 $\mu$ g
3w	30 $\mu$ l	0.005	0.004	1.3	0.006	0.2 $\mu$ g
3e <sub>1</sub>	30 $\mu$ l	0.365	0.187	1.95	0.913	27.4 $\mu$ g
3e <sub>2</sub>	30 $\mu$ l	0.049	0.026	1.88	0.123	3.7 $\mu$ g
4f	30 $\mu$ l	0.043	0.025	1.72	0.054	1.6 $\mu$ g
4w	30 $\mu$ l	0.005	0.004	1.3	0.006	0.2 $\mu$ g
4e <sub>1</sub>	30 $\mu$ l	0.228	0.118	1.93	0.570	17.1 $\mu$ g **
4e <sub>2</sub>	30 $\mu$ l	0.012	0.008	1.5	0.030	0.9 $\mu$ g
* - The mass indicated is for the original sample based on the elution volume and the A260 reading, which reads 1 AU for 50 g/ml. ** - The yield of de <sub>1</sub> is underrepresented, due to less RNA contaminants in the preparation as indicated in the gel.						

The results set forth in Table 2 above, those obtained with the agarose gel run, indicate that excellent recovery was obtained using Tube 1 containing the ACA 44 media, and the gel electrophoresis results indicate that the ACA 44 media in Tube 1 properly desalted the desired plasmid product.

5

### EXAMPLE 3

Each of two wells of a 96-well filter plate (Polyfiltronics, Rockland, MA USA), were loaded with 150  $\mu$ l of 40% PLASMIDEX™ 20 $\mu$  slurry, and designated Wells 1 and 2. A third well of the 96-well filter plate was loaded with 500  $\mu$ l of 50 % ACA 34 slurry, and designated Well 3. The plate was then spun for 1 minute using a Beckman G6  
10 centrifuge at 2000 rpm (360g) to remove excess fluid. Thereafter, in Well 3, 150  $\mu$ l of 40% PLASMIDEX™ 20 $\mu$  slurry was added on top of the ACA 34, and the plate was spun again for 1 minute.

Each of Wells 1 to 3 were then preequilibrated with 600  $\mu$ l of 0.5 M NaCl, 50 mM Tris pH 7.0. Thereafter, 600  $\mu$ l of a sample from Example 1, which comprise a clear  
15 lysate from a culture of *E. coli* DH5 $\alpha$  containing pSV-  $\beta$ GAL (the desired plasmid product) and undesirable contaminants, was added to each of Wells 1, 2, and 3. The plate was then spun for 5 minutes in the centrifuge. The flow through from each well was collected, and designated as samples 1f, 2f, and 3f, respectively.

Each well was then washed with 600  $\mu$ l of 0.5 M NaCl, 50 mM Tris pH 7.0, and  
20 the plate was then spun for 3 minutes in the centrifuge. The wash from Wells 1, 2, and 3 were collected and labeled as samples 1w, 2w, and 3w, respectively. Thereafter, Well 3 was loaded with 600  $\mu$ l distilled water (as preferred buffer (2)).

Each well was then eluted with 100  $\mu$ l of 2 M NaCl, 50 mM Tris pH 8.5; and  
25 soaked for 2 minutes. Thereafter, the plate was spun in the centrifuge for 2 minutes and the elution samples were collected and designated as samples 1e, 2e, and 3e, respectively.

Standard isopropanol precipitation was then performed on each of the crude  
lysate samples, flow through samples, wash samples, and elution samples 1e and 2e, wherein a volume of isopropanol equal to about 70% of the volume of the sample is added to each sample, vortexed, and allowed to sit on ice for about 60 minutes. These  
30 samples were then centrifuged in a Beckman G6 centrifuge for about 10 minutes at about 14,000 rpm, and the supernatant decanted. Each tube was then washed with 600  $\mu$ l of 70% ethanol at - 20°C, centrifuged for 6 minutes, and the supernatant decanted. The



tubes were then allowed to air dry for 20 minutes, and were resuspended in 100  $\mu$ l of TE Buffer.

5  $\mu$ l of each sample collected, as well as 5  $\mu$ l of the crude lysate samples used, were then loaded onto a 1 % agarose gel run at 100 V for 60 minutes. The lanes of the gel contained the following samples: lane 1 was loaded with 5  $\mu$ l of isopropanol precipitated  
5 crude lysate sample used in Wells 2 and 3; lane 2 was loaded with 5  $\mu$ l of isopropanol precipitated crude lysate sample used in Well 1; lanes 4 through 6 were loaded with 5  $\mu$ l of samples 1f, 1w, and 1e, respectively; lanes 8 through 10 were loaded with 5  $\mu$ l of samples 2f, 2w, and 2e, respectively; and lanes 12 through 14 were loaded with 5  $\mu$ l of  
10 samples 3f, 3w, and 3e, respectively.

Results from the agarose gel run, especially for the elution sample 3e (lane 14), indicate that good desalting of the plasmid sample was obtained using the ACA 34 media situated in the well beneath the PLASMIDEX™ 20 $\mu$  media.

#### EXAMPLE 4

15 Each of two, 3 mm diameter tubes having a porous frit in the bottom were loaded with 150  $\mu$ l of a 75% GF05 media slurry, and a third tube was loaded with 100  $\mu$ l of the 75% GF05 media slurry. The tubes were then vacuumed from the bottom to remove excess fluid, and designated as Tubes 1, 2, and 3, respectively. Each of Tubes 1, 2, and 3 were then loaded with 37.5  $\mu$ l of a 40% PLASMIDEX™ 20 $\mu$  slurry (BioSeptra Inc.,  
20 Marlborough, MA USA), and vacuumed from the bottom to remove excess liquid.

In addition, a well of a 96-well filter plate (Polyfiltronics, Rockland, MA USA) was loaded with 400  $\mu$ l of a 75% GF05 media slurry, and then to remove excess fluid, the plate was spun in a Beckman G6 centrifuge for about 2 minutes at 1800 rpm. The well was then loaded with 375  $\mu$ l of a 40% PLASMIDEX™ 20 $\mu$  slurry, and spun in the  
25 centrifuge for about 3 minutes at 1800 rpm. A porous polypropylene frit having pores of about 7  $\mu$ m, was placed on top of the packed PLASMIDEX™ 20 $\mu$  media, and this well is designated Tube 4.

The tubes were then all preequilibrated with 400  $\mu$ l of 0.5 M NaCl, 50 mM Tris pH 7.0. Thereafter, 400  $\mu$ l of samples comprising clear *E. coli* lysates according to  
30 Example 1 containing the desired pSV- $\beta$ GAL plasmid product and undesirable contaminants, were then added to each of Tubes 1 to 3, and 600  $\mu$ l of a clear *E. coli* lysate sample was added to Tube 4. The tubes were vacuumed and the flow through from each

tube was collected, and designated as samples 1f, 2f, 3f, and 4f, respectively.

Each tube was then washed with 400  $\mu$ l of 0.5 M NaCl, 50 mM Tris pH 7.0, and the wash from Tubes 1 to 4 was collected and labeled as samples 1w, 2w, 3w, and 4w, respectively. Thereafter, each tube was loaded with 400  $\mu$ l of 50 mM Tris pH 7.0 (as preferred buffer (2)).

Tubes 1 and 2 were then eluted twice with 25  $\mu$ l of 1.5 M NaCl, 50 mM Tris pH 8.5 with 2.5  $\mu$ g/ml RNase. After each elution step, the tubes were vacuumed and elution samples were collected, and were designated 1e<sub>1</sub>, 1e<sub>2</sub>, 2e<sub>1</sub>, and 2e<sub>2</sub>, respectively. Tube 3 was eluted twice with 25  $\mu$ l of 2M NaCl, 50 mM Tris pH 8.5, and samples were collected after each elution step as above, and designated 3e<sub>1</sub> and 3e<sub>2</sub>. Tube 4 was eluted first with 100  $\mu$ l of 1 M NaCl, 50 mM Tris pH 8.5, which was allowed to soak for 2 minutes, and then the plate was spun on the centrifuge for 5 minutes, and an elution sample designated 4e<sub>1</sub> was collected. Tube 4 was then eluted a second time with 100  $\mu$ l of 2 M NaCl, 50 mM Tris pH 8.5, which was allowed to soak for 2 minutes, and then the plate was spun on the centrifuge for 5 minutes, and an elution sample designated 4e<sub>2</sub> was collected.

An EcoRI (10 xx) restriction enzyme digest solution was made by combining 60  $\mu$ l of distilled water, 10  $\mu$ l of 10x buffer H, and 5  $\mu$ l of EcoRI. Similarly, an HindIII (10xx) restriction enzyme digest solution was made by combining 60  $\mu$ l of distilled water, 10  $\mu$ l of 10x buffer H, and 5  $\mu$ l of HindIII.

EcoRI digestion samples were then made for i) samples 1e<sub>1</sub>, 2e<sub>1</sub>, 2e<sub>2</sub>, 3e<sub>1</sub>, 4e<sub>1</sub>, and 4e<sub>2</sub> of this example, ii) sample 4e<sub>1</sub> from Example 2, and iii) crude *E. coli* DH5 $\alpha$  lysate sample by mixing in a tube 7.5  $\mu$ l of EcoRI restriction enzyme digest solution with 2.5  $\mu$ l of the sample, allowing to stand at 37 °C for 2 hours, and then adding 2.5  $\mu$ l of 6x loading buffer.

Similarly, HindIII digestion samples were made for i) samples 1e<sub>1</sub>, 2e<sub>1</sub>, 2e<sub>2</sub>, 3e<sub>2</sub>, 4e<sub>1</sub>, and 4e<sub>2</sub> of this example, ii) sample 4e<sub>1</sub> from Example 2, and iii) crude *E. coli* DH5 $\alpha$  lysate sample by mixing in a tube 7.5  $\mu$ l of HindIII restriction enzyme digest solution with 2.5  $\mu$ l of the sample, allowing to stand at 37 °C for 2 hours, and then adding 2.5  $\mu$ l of 6x loading buffer.

5  $\mu$ l of each sample were then loaded onto a 1 % agarose gel in the lanes indicated Table 3 below, and the gel was run at 100 V for 60 minutes.

**Table 3**

LANE NO.	SAMPLE	RESTRICTION ENZYME
1	$\lambda$ HindIII marker	HindIII
2	crude <i>E.coli</i> DH5 $\alpha$ lysate sample used in Example 4	none
3	1e <sub>2</sub> from Example 4	none
4	3e <sub>2</sub> from Example 4	none
5	1e <sub>1</sub> of Example 4	EcoRI
6	1e <sub>1</sub> of Example 4	HindIII
7	2e <sub>1</sub> of Example 4	EcoRI
8	2e <sub>1</sub> of Example 4	HindIII
9	2e <sub>2</sub> of Example 4	EcoRI
10	2e <sub>2</sub> of Example 4	HindIII
11	3e <sub>1</sub> of Example 4	EcoRI
12	3e <sub>2</sub> of Example 4	HindIII
13	crude <i>E.coli</i> DH5 $\alpha$ lysate	EcoRI
14	crude <i>E.coli</i> DH5 $\alpha$ lysate	HindIII
15	4e <sub>1</sub> of Example 2	EcoRI
16	4e <sub>1</sub> of Example 2	HindIII
17	4e <sub>1</sub> from Example 4.	EcoRI
18	4e <sub>1</sub> from Example 4	HindIII
19	4e <sub>2</sub> from Example 4	EcoRI
20	4e <sub>2</sub> from Example 4	HindIII

The results obtained with the gel indicate that the present invention provides good separation of the desired plasmid product from the sample, and the resulting purified plasmid product may be satisfactorily used in subsequent processing steps

The embodiments of the present invention described above are intended to be merely exemplary and those skilled in the art will recognize, or be able to ascertain using no more than routine experimentation, numerous equivalents to the specific procedures described herein. All such equivalents are considered to be within the scope of the present invention and are covered by the following claims.

The contents of all references described herein are hereby incorporated by reference. Other embodiments are within the following claims.

### Claims

What is claimed is:

1. A device for purification of biological molecules comprising:  
a housing, wherein said housing has an outlet at a bottom end and a porous  
5 material disposed at the bottom end;  
a size exclusion media portion comprising a volume of a size exclusion media  
packed in the housing on top of said porous material; and  
an adsorptive media portion comprising a volume of adsorptive media packed in  
the housing on top of said size exclusion media portion.
2. The device of Claim 1, further comprising a reservoir, wherein said reservoir  
is disposed above the adsorptive media portion of the device.
3. The device of Claim 1, further comprising a second removable porous  
material, wherein said second removable porous material is disposed on top of said  
adsorptive media portion of the device.
4. The device of Claim 1, wherein the housing comprises a well of a multiwell plate.
5. The device of Claim 1, wherein the adsorptive media portion comprises  
adsorptive media which bind a biological molecule in the presence of a first buffer and  
elutes said biological molecule in the presence of a second buffer.
6. The device of Claim 4, wherein the adsorptive media is selected from the  
group consisting of ion exchange media, affinity media, normal phase media, reverse  
phase media, metal chelating media, and hydroxyapatite media.
7. The device of Claim 1, wherein a packed volume of the adsorptive media  
packed in the device is in the range of about 10  $\mu$ l to about 2000  $\mu$ l.
8. The device of Claim 7, wherein the packed volume of the adsorptive media in  
the device is in the range of about 10  $\mu$ l to about 50  $\mu$ l.

9. The device of Claim 8, wherein the packed volume of the adsorptive media in the device is in the range of about 15  $\mu$ l to about 25  $\mu$ l.

10. The device of Claim 1, wherein said size exclusion media is a size exclusion chromatography desalting media.

11. The device of Claim 1, wherein a packed volume of the size exclusion media in the device is in the range of about 30  $\mu$ l to about 6000  $\mu$ l.

12. The device of Claim 11, wherein the packed volume of the size exclusion media in the device is in the range of about 40  $\mu$ l to about 300  $\mu$ l.

13. The device of Claim 12, wherein the packed volume of the size exclusion media in the device is in the range of about 45  $\mu$ l to about 100  $\mu$ l.

14. The device of Claim 1, wherein said porous material is a porous polypropylene frit.

15. A method for separating biological molecules of interest from a sample comprising the steps of:

- (a) preequilibrating the device of Claim 1 with a buffer solution;
- (b) loading the resulting preequilibrated device with a sample comprising a mixture of the biological molecules of interest and undesired impurities;
- (c) washing the loaded device with a buffer (1);
- (d) charging the device with a preferred buffer (2), wherein said preferred buffer (2) saturates the size exclusion media portion of the device;
- (e) eluting the biological molecules of interest with a volume an elution buffer (3); and
- (f) collecting the resulting elutant, wherein said elutant comprises the biological molecules of interest in the preferred buffer (2).

16. The method of Claim 15, wherein said buffer (1) removes loosely bound impurities from the device while leaving the desired biological molecules of interest sorbed to the adsorptive media portion of the device.

17. The method of Claim 15, wherein the volume of elution buffer (3) present is in the range of about 5% to about 50% of the volume of size exclusion media packed into the device.

18. The method of Claim 15, wherein the preferred buffer (2) is present in a volume about equal to a total volume of media in the device, wherein said total volume is the volume of size exclusion media plus the volume of adsorption media present in the device.

19. The method of Claim 18, wherein the volume of preferred buffer (2) further contains an additional volume in the range of about 1% to about 600% of the total volume of media in the device.

20. The method of Claim 19, wherein said additional volume is in the range of about 5% to about 400% of the total volume of media in the device.

21. The method of Claim 20, wherein said additional volume is in the range of about 10% to about 60% of the total volume of media in the device.

22. The method of Claim 15, wherein the biological molecules of interest are selected from the group consisting of plasmid DNA and genomic DNA.

23. A device for purification of biological molecules comprising:  
a housing, wherein said housing has an outlet at a bottom end and a porous material disposed at the bottom end;  
a size exclusion media portion comprising a volume of a size exclusion media packed in the housing on top of said porous material; and  
a surfactant portion comprising a surfactant layer disposed on top of said size exclusion media portion.

24. The device of Claim 23, wherein said surfactant layer comprises a surfactant selected from the group consisting of sodium dodecyl sulfate, Triton X100, Triton X114, and Brij.

25. A method for purifying a biological molecule of interest, comprising the steps of:

(a) precharging the device of Claim 23 with a preferred buffer (2), wherein said preferred buffer (2) saturates the size exclusion media portion of the device;

5 (b) loading the resulting precharged device with a sample comprising a mixture of the biological molecules of interest and undesired impurities;

(c) eluting the biological molecules of interest with a volume any buffer ;  
and

(d) collecting the resulting elutant, wherein said elutant comprises the biological molecules of interest in the preferred buffer (2).

COFFMAN

Figure 1





Figure 2





# INTERNATIONAL SEARCH REPORT

International Application No.

PCT/US 98/13163

**A. CLASSIFICATION OF SUBJECT MATTER**  
IPC 6 B01D15/08 G01N30/60

According to International Patent Classification (IPC) or to both national classification and IPC

**B. FIELDS SEARCHED**

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 G01N B01D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

**C. DOCUMENTS CONSIDERED TO BE RELEVANT**

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	US 4 719 011 A (MEYER DANNY D ET AL) 12 January 1988 see column 12, line 53-68; figures 5, 27 ---	1-3
A	DE 41 39 664 A (DIAGEN INST MOLEKULARBIO) 3 June 1993 see column 2, line 23 - column 4, line 13; figure 2; example 5 ---	1
A	US 4 510 058 A (SHIMONI MOSHE ET AL) 9 April 1985 see column 1, line 41-42 see column 1, line 64 see column 2, line 12-13 see column 7, line 54-60; figure 8 ---	1
A	JP 60 227166 A (DAICEL KAGAKU KOGYO KK) 12 November 1985 ---	1
-/--		



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

\* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

12 October 1998

Date of mailing of the international search report

21/10/1998

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Zinngrebe, U

# INTERNATIONAL SEARCH REPORT

Internat. J. Patent Classification No.

PCT/US 98/13163

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 252 216 A (FOLENA-WASSERMAN GAIL ET AL) 12 October 1993 see column 1, line 5-9 see column 2, line 46-59 ---	1
A	US 4 283 199 A (SZABO ELEK I) 11 August 1981 see column 3, line 5 - column 4, line 33 see column 4, line 60 - column 5, line 2; figure 1 see column 7, line 26-31 ---	1
X	US 4 515 889 A (KLOSE SIGMAR ET AL) 7 May 1985 see column 3, line 38 - column 4, line 8 see column 8, line 47-57 see column 8, line 65 see figure 5 ---	23
A	EP 0 444 441 A (HEWLETT PACKARD CO) 4 September 1991 see column 10, line 12-13 ---	23
A	US 5 417 923 A (BOJANIC DEJAN (GB); MERSON JAMES R (GB)) 23 May 1995 see line A; figure 3 -----	4

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 98/13163

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4719011 A	12-01-1988	US 5013433 A	07-05-1991
		US 4882047 A	21-11-1989
DE 4139664 A	03-06-1993	DE 59205979 D	15-05-1996
		WO 9311218 A	10-06-1993
		WO 9311221 A	10-06-1993
		EP 0616638 A	28-09-1994
		EP 0616639 A	28-09-1994
		JP 7501222 T	09-02-1995
		JP 7501223 T	09-02-1995
US 4510058 A	09-04-1985	AT 394454 B	10-04-1992
		AU 568462 B	24-12-1987
		AU 1795583 A	16-02-1984
		BE 897508 A	01-12-1983
		CA 1214398 A	25-11-1986
		CH 662062 A	15-09-1987
		DE 3329288 A	16-02-1984
		FR 2532055 A	24-02-1984
		GB 2125312 A, B	07-03-1984
		JP 1753187 C	23-04-1993
		JP 4041304 B	07-07-1992
		JP 60035257 A	23-02-1985
		NL 8302726 A	01-03-1984
		SE 457606 B	16-01-1989
		SE 8304349 A	16-02-1984
JP 60227166 A	12-11-1985	JP 1853861 C	07-07-1994
US 5252216 A	12-10-1993	AU 3932493 A	21-10-1993
		CA 2132533 A	30-09-1993
		EP 0643608 A	22-03-1995
		FI 944412 A	23-09-1994
		JP 7505469 T	15-06-1995
		MX 9301655 A	31-03-1994
		NO 943546 A	23-11-1994
		NZ 251601 A	24-03-1997
		WO 9318835 A	30-09-1993
		ZA 9302015 A	21-09-1994

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Publication No

PCT/US 98/13163

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
US 4283199 A	11-08-1981	NONE	
US 4515889 A	07-05-1985	DE 3044385 A AU 533869 B AU 7780981 A CA 1179865 A DD 202072 A EP 0052769 A JP 1034348 B JP 1551391 C JP 57114859 A	24-06-1982 15-12-1983 15-07-1982 25-12-1984 24-08-1983 02-06-1982 19-07-1989 23-03-1990 16-07-1982
EP 0444441 A	04-09-1991	DE 69122280 D DE 69122280 T JP 7072129 A US 5135657 A	31-10-1996 24-04-1997 17-03-1995 04-08-1992
US 5417923 A	23-05-1995	NONE	

**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☒ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☒ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**

**THIS PAGE BLANK (USP 100)**